New drug duo aims to outsmart resistant lung cancer
Disease control
Not yet recruiting
This study is testing whether adding a new drug called capivasertib to a standard lung cancer drug (osimertinib) can help control advanced non-small cell lung cancer that has specific genetic changes and has started growing again after initial treatment. It will involve about 53 …
Phase: PHASE1, PHASE2 • Sponsor: Shanxi Province Cancer Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC